IPN01194 / Ipsen, AGV Discovery - LARVOL DELTA

A phase I/IIa first-in-human, open label study to investigate ERK1/2 inhibitor IPN01194 in adults with advanced solid tumours (ESMO 2025) - P1/2 | "Legal entity responsible for the study Ipsen. Funding This study is sponsored by Ipsen."

Clinical • First-in-human • Metastases • P1/2 data • Head and Neck Cancer • Melanoma • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • BRAF • KRAS

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours (clinicaltrials.gov) - P1/2 | N=220 | Recruiting | Sponsor: Ipsen | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatology • Melanoma • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours (clinicaltrials.gov) - P1/2 | N=220 | Not yet recruiting | Sponsor: Ipsen

Metastases • New P1/2 trial • Colorectal Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatology • Melanoma • Oncology • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck